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ABSTRACT A clinical Pseudomonas aeruginosa isolate resistant to all -lactams, in-
cluding ceftolozane-tazobactam and carbapenems, was recovered. It belonged to se-
quence type 235 and produced the extended-spectrum -lactamase (ESBL) GES-6
differing from GES-1 by two amino acid substitutions (E104K and G170S). GES-6
possessed an increased hydrolytic activity toward carbapenems and to ceftolo-
zane and a decreased susceptibility to -lactamase inhibitors compared to GES-1,
except for avibactam. We show here that resistance to ceftolozane-tazobactam
may occur through acquisition of a speciﬁc ESBL in P. aeruginosa but that
ceftazidime-avibactam combination remains an effective alternative.
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Multidrug resistance, including carbapenem molecules, is currently a commonfeature encountered among Pseudomonas aeruginosa isolates. This is the conse-
quence of the accumulation of multiple resistance determinants within that species, in
addition to its intrinsic reduced susceptibility to many drugs (1). Resistance to carbap-
enems is either due to porin deﬁciency or to the acquisition of carbapenemase genes.
Acquired carbapenemases are increasingly reported in P. aeruginosa, and there is
currently a variety of those enzymes that have been identiﬁed in that species. The most
commonly identiﬁed carbapenemases encountered in that species are the metallo-
-lactamases (IMP, VIM, SPM, GIM, and NDM enzymes) belonging to the Ambler
class B (1). In addition, class A (KPC) and class D (OXA-181) carbapenem-hydrolyzing
-lactamases have been rarely identiﬁed in P. aeruginosa (2–4). One speciﬁc group of
-lactamases quite frequently identiﬁed in P. aeruginosa corresponds to GES enzymes,
with GES-1 being an extended-spectrum -lactamase sparing carbapenems (5), while
the GES-2 and GES-5 variants have been shown to possess signiﬁcant carbapenemase
activities (6). GES-6 was ﬁrst identiﬁed in a Klebsiella pneumoniae isolate from Greece (7)
and later detected in Enterobacter cloacae and Pseudomonas aeruginosa clinical isolates
recovered in Belgium (8) and Portugal (9), respectively, but the hydrolytic properties of
GES-6 have not been characterized.
The ceftolozane-tazobactam (C/T) association, combining a novel cephalosporin
with an established -lactamase inhibitor, has recently been launched and is particu-
larly effective against multidrug-resistant (including carbapenem-resistant) P. aerugi-
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nosa isolates (10). Although not affected by efﬂux pumps or porin loss, C/T was shown
to be ineffective against carbapenemase-producing isolates, including OXA-539-, KPC-,
and metallo--lactamase producers (11–13). This drug combination is licensed for
complicated intra-abdominal infections and complicated urinary tract infections, al-
though there are reports of successful treatments of ventilator-associated pneumonia
(14, 15). The EUCAST breakpoint for C/T has been established as resistant at 4 g/ml
for P. aeruginosa (16).
There have been several reports of successful clinical experiences with this new drug
combination for treating infections caused by multidrug-resistant P. aeruginosa; how-
ever, the emergence of resistance on therapy has been reported (11). In different
studies evaluating the efﬁcacy of C/T against P. aeruginosa isolates, an overall excellent
activity was reported, even though resistant isolates were observed, corresponding
mainly to overproducers of peculiar AmpC derivatives. Some of these isolates actually
accumulate a signiﬁcant number of other narrow-spectrum -lactamases (17–20).
Our study was initiated by the isolation of a clinical P. aeruginosa isolate that is
multidrug resistant and that shows particular resistance to C/T. Our goal was to
decipher the molecular mechanism(s) leading to this resistance phenotype.
RESULTS AND DISCUSSION
Features of the clinical isolate. P. aeruginosa strain BOR was recovered from a
respiratory specimen obtained from a 26-year-old patient hospitalized at an intensive
care unit at Hospital Pellegrin (Bordeaux, France) in November 2017. A patient with
congestive heart failure was transferred from a hospital in Portugal. She developed
fever and was diagnosed with a respiratory tract infection. P. aeruginosa BOR was
resistant to all -lactams, including carbapenems, except to aztreonam (Table 1). This
isolate was additionally resistant to all tested aminoglycosides (with a plazomicin MIC
of 16 g/ml) and ﬂuoroquinolones, but it remained susceptible to fosfomycin and
colistin. Of note, this isolate was resistant to the C/T combination (MIC of 32 g/ml)
(Table 1), even though the patient did not receive this antibiotic previously. Interest-
TABLE 1 -Lactams MICs for various P. aeruginosa and E. coli strains examined in this studya
-Lactam(s)b
MIC (g/ml)











Amoxicillin 512 512 512 512 512 512 4
Amoxicillin  CLA 512 512 512 512 16 32 3
Ticarcillin 512 512 256 32 512 64 8
Ticarcillin  CLA 128 128 32 4 512 2 1
Piperacillin 512 128 64 4 256 16 2
Piperacillin  TZB 32 32 4 1 32 1 0.5
Cefoxitine 512 512 512 512 128 2 2
Ceftazidime 128 128 128 8 64 8 0.25
Ceftazidime  CLA 64 128 32 1 16 0.5 0.5
Ceftazidime  TZB 128 128 16 2 32 0.5 0.5
Ceftazidime  AVI 2 2 2 1 1 0.25 0.25
Cefotaxime 512 64 64 16 32 8 0.06
Cefotaxime  CLA 256 32 32 16 0.5 0.25 0.06
Cefotaxime  TZB 128 32 16 16 0.5 0.25 0.06
Cefepime 32 32 8 4 0.5 2 0.5
Ceftolozane 128 128 32 2 128 32 0.25
Ceftolozane  CLA 64 128 16 0.5 64 16 0.25
Ceftolozane  TZB 32 64 16 0.25 64 8 0.25
Aztreonam 8 2 2 3 0.38 0.09 0.06
Imipenem 16 2 1 1 0.25 0.12 0.06
Meropenem 64 32 0.5 0.5 0.12 0.06 0.06
Ertapenem 256 256 8 8 2 0.06 0.06
aP. aeruginosa clinical isolate BOR producing GES-6, P. aeruginosa transformants PAO1 producing GES-6 and GES-1, respectively, E. coli TOP10 transformants PAO1
producing GES-6 and GES-1, respectively, and P. aeruginosa and E. coli recipient strains.








ingly, this isolate remained susceptible to ceftazidime-avibactam (CZA) at an MIC at
2 g/ml (EUCAST breakpoint being at 8 g/ml for P. aeruginosa). The patient was
successfully treated with a combination of aztreonam, fosfomycin, and colistin.
Identiﬁcation of the GES-6 -lactamase. The production of an extended-spectrum
-lactamase (ESBL) and a carbapenemase was assessed using Rapid ESBL NP and Rapid
Carba NP tests, respectively (21, 22). Both tests yielded positive results. PCR ampliﬁca-
tion, followed by sequencing, did not identify any carbapenemase gene but did identify
a blaGES-type ESBL gene. Further sequencing identiﬁed the blaGES-6 gene. -Lactamase
GES-6 differs from GES-1 by two amino acid substitutions (Glu104Lys and Gly170Ser)
(6). Position 170 of GES-1 was previously shown to be critical, since a Gly-to-Asn change
observed in GES-2 was shown to slightly expand the hydrolysis spectrum toward
cephamycins and carbapenems (23). Then, the Gly-to-Ser substitution identiﬁed in
GES-5 showed that the latter enzyme might deﬁnitely be considered a carbapenemase
(24, 25). Here, the same Gly170Ser substitution was identiﬁed in GES-6, possibly leading
to a signiﬁcant carbapenemase activity, explaining the positivity of the Rapid Carba NP
test. Apart from this critical Ser residue at position 170, the Lys at position 104 was
previously shown to expand the hydrolytic activity of GES enzymes toward several
-lactams, including oxyimino-cephalosporins (26).
In addition, the intrinsic blaampC gene and its upstream-located sequences (contain-
ing the promoter sequences) were ampliﬁed by PCR and sequenced. It revealed a
perfect identity with those of the wild-type strain PAO1, therefore suggesting that this
blaampC gene was expressed at low level. This result correlates with the identical MIC
value of aztreonam (6 g/ml) observed for P. aeruginosa BOR when testing on Mueller-
Hinton agar plates supplemented or not with cloxacillin (200 g/ml).
Phylogenetic analysis.Multilocus sequence typing analysis performed as described
previously (27) showed that isolate BOR belonged to sequence type 235 (ST235). This
clone has been previously identiﬁed in different parts of the world and is considered
“high-risk” in terms of dissemination (9). Of note, a GES-6-producing ST235 isolate was
very recently identiﬁed in Portugal, but the susceptibility of that isolate to C/T was not
evaluated (9). Since the patient from which isolate BOR was recovered had been
transferred from Portugal, it is likely that our isolate corresponded to the same clone.
Relative properties of GES-6 and GES-1. Expression of the blaGES-1 and blaGES-6
genes in E. coli TOP10 conferred resistance or reduced susceptibility to all -lactams
except aztreonam (Table 1). However, MICs of imipenem were higher for Escherichia
coli-producing GES-6 than GES-1, conﬁrming that the Ser170 residue was involved in
this higher carbapenemase activity of GES-6. Interestingly, MIC of ceftolozane was
4-fold higher for the GES-6- than for the GES-1-producing E. coli recombinant strain (128
versus 32 g/ml). Furthermore, the addition of tazobactam (4 g/ml) to ceftolozane
only marginally decreased the MIC of ceftolozane (128 to 64 g/ml) for the GES-6 E. coli
recombinant strain, while it decreased to 8 g/ml for the GES-1 producer.
Besides the activity of C/T combination, we measured the activity of the recently
launched association CZA. Very interestingly, we observed that this combination re-
mained very effective against both the GES-6 and GES-1 producers, while the
ceftazidime-clavulanate or C/T combinations did not show signiﬁcant efﬁcacies against
the GES-6 producer but were excellent against the GES-1 producer (Table 1). This
observation suggested that avibactam is an excellent inhibitor of GES-6 activity, in
contrast to other -lactamase inhibitors.
In order to evaluate the impact of blaGES-6 expression in P. aeruginosa compared to
blaGES-1, recombinant plasmids were transformed in wild-type P. aeruginosa PAO1. MIC
of ceftolozane was 2-fold higher in GES-6 than in the GES-1 producer (128 versus
32 g/ml), and the addition of clavulanic acid or tazobactam did not signiﬁcantly lower
the MIC values (Table 1). Of note, the MICs of CZA remained in the susceptibility range
for both transformants, further highlighting that avibactam very effectively inhibits








-Lactamase GES-6 hydrolyzed all tested -lactams, including ceftazidime, cefo-
taxime, cefoxitin, and carbapenems, but spared aztreonam, presenting a substrate
proﬁle mirroring that of metallo--lactamases. Kinetic data showed that GES-6 signiﬁ-
cantly hydrolyzed imipenem, with a catalytic efﬁciency above that of the broad-
spectrum cephalosporins (Table 2). In contrast, the catalytic activity of GES-6 for
ceftazidime was much less than that of GES-1 (Table 2). In addition, GES-6 hydrolyzed
ceftolozane signiﬁcantly but only twice more than GES-1 (Table 2). The reduced activity
of C/T against GES-6 producers might thus be explained much more by a reduced
sensitivity to tazobactam rather than an increased hydrolysis activity toward ceftolo-
zane.
Since data obtained through this study suggested that GES-6 likely exhibited
reduced sensitivity toward tazobactam, the determination of 50% inhibitory concen-
trations (IC50) but also on-rate (k2/K) and off-rate (koff) were performed. Using nitroceﬁn
as the substrate, the comparative inhibitory activities of clavulanic acid, tazobactam,
and avibactam were evaluated for GES-6 and GES-1, respectively. Signiﬁcant differences
were observed for clavulanic acid and tazobactam (with sharped reduction of sensitivity
toward GES-6), while the activity of avibactam remained almost identical (Table 3). This
shows that the Ser residue at position 170, while signiﬁcantly impacting the sensitivity
of GES-6 respect to the “classical” -lactamase inhibitors clavulanic acid and tazobac-
tam, does not have any signiﬁcant impact on the efﬁcacy of the recently marketed
avibactam molecule (which is not a -lactam molecule by contrast to clavulanic acid or
tazobactam).
Genetic support of blaGES-6. Plasmid DNA of P. aeruginosa BOR was extracted by
using the Kieser method (28) and analyzed by agarose gel electrophoresis. No plasmid
could be visualized, and electro-transformation experiments performed using electro-
competent P. aeruginosa PAO1 recipient strain remained unsuccessful. Then, PCR
mapping was performed and conﬁrmed that the blaGES-6 gene was present in the same
genetic context than that of the blaGES-6-positive ST235 clone from Portugal, therefore
TABLE 2 Kinetic parameters of puriﬁed -lactamase GES-6a
-Lactam
GES-6 GES-1
kcat (s1) Km (M) kcat/Km (mM1 s1) kcat (s1) Km (M) kcat/Km (mM1 s1)
Benzylpenicillin 90 450 200 3 40 75
Amoxicillin 40 300 130 10 200 50
Ticarcillin 3 110 30 0.3 400 0.7
Piperacillin 20 300 660 8 900 9
Cephalothin 110 170 650 180 3,400 50
Cefoxitin 12 1,600 7 1 30 30
Cefotaxime 11 2,200 5 70 4,600 15
Ceftazidime 13 3,300 4 380 2,000 190
Cefepime 2 1,400 1.5 3 1,800 1.6
Ceftolozane 10 1,800 5.5 5 2,200 2.3
Aztreonam 0.1 ND ND 0.1 ND ND
Imipenem 0.25 8 30 0.003 45 0.06
aThat is, in comparison to previously reported values of GES-1 (5). Standard deviations were below 15%. ND, not determined due to a low initial rate of hydrolysis.
kcat, catalytic efﬁciency; Km, Michaelis constant; kcat/Km, speciﬁcity constant.
TABLE 3 IC50 and steady-state kinetic inhibition parameters of different -lactamase inhibitors against GES-6 and GES-1
Inhibitor
IC50 (M)a Ki (M)b KI (M)c kinact (s1)d kinact/KI (M–1 s1)
GES-6 GES-1 GES-6 GES-1 GES-6 GES-1 GES-6 GES-1 GES-6 GES-1
Clavulanic acid 146 5.5 68 1.96 21 3.75 0.048 0.080 0.002 0.021
Tazobactam 16 3.6 7.7 0.9 5.15 0.8 0.11 0.046 0.021 0.06
Avibactam 3.7 3 2 1.5 1.1 0.83 0.09 0.063 0.08 0.076
aIC50 represents the concentration of a drug that is required for 50% inhibition of the enzymatic activity.
bKi corresponds to the relative koff/kon ratio for the inhibitor for the enzyme.
cKI corresponds to the concentration of inhibitor required to reach 1/2kinact.








assessing its chromosomal location (29). Noteworthy, the blaGES-6 gene was located
into a class 1 integron (In1076) being itself located into a chromosomal Integrative
Conjugative Element (ICE) named ICEPae690 (29).
Conclusion.We reported here a multidrug-resistant P. aeruginosa isolate producing
the GES-6 enzyme which is not only an ESBL but whose substrate proﬁle also encom-
passes carbapenems and whose sensitivity to -lactamase inhibitors is actually dimin-
ished compared to classical ESBLs. In a way, the substrate proﬁle of GES-6 mirrors that
of metallo--lactamases, with a broad-spectrum hydrolysis activity, including carbap-
enems, and some resistance to inhibitors, with the exception of avibactam. We also
showed that -lactamase GES-6 was responsible for acquired resistance to C/T, which
usually is an effective therapeutic option for treatment of infections caused by
multidrug-resistant P. aeruginosa. It is worth noting that GES-6 showed increased
activity toward ceftolozane combined with reduced afﬁnity toward tazobactam, both
factors leading to the resistance phenotype observed. Increased activity toward cef-
tolozane may well be related to the presence of both Lys140 and Ser170, while reduced
sensitivity to tazobactam is likely related primarily to Ser170.
GES-6 was produced by an ST235 strain, which is now increasingly reported.
Recently, a fatal case of infection by an ST235 isolate was reported in the United
Kingdom in a patient with cystic ﬁbrosis who experienced a failure in C/T treatment
(15). However, whether this strain produced GES-6 remains unknown. Very interest-
ingly, isolate BOR remained susceptible to the CZA combination, and our data indicate
that GES-6 is signiﬁcantly inhibited by avibactam. This recent combination might offer
an effective therapeutic option for treating infections caused by GES-6-producing P.
aeruginosa.
MATERIALS AND METHODS
Bacterial strains and plasmids. P. aeruginosa R1190 producing GES-1 and P. aeruginosa BOR
producing GES-6 were clinical isolates used in the present study, P. aeruginosa PAO1 and Escherichia coli
TOP10 were used as recipient strains. Plasmid pUCp24 (30) was used as shuttle vector for cloning and
expression in E. coli and P. aeruginosa recipient strains.
Susceptibility testing. Susceptibility testing was performed by disk diffusion assay (Sanoﬁ-
Diagnostic Pasteur, Marnes-la-Coquette, France) as previously described (31). Results were interpreted
according to the CLSI guidelines (32). MICs were determined by Etest (AB bioMérieux; Solna, Sweden) on
Mueller-Hinton agar plates at 37°C. Production of MBL was tested using Etest MBL (AB bioMérieux). The
antimicrobial agents were obtained from standard laboratory powders and were used immediately after
their solubilization. The agents and their sources were as follows: amoxicillin, piperacillin, cefepime,
cephalothin, ceftazidime, and clavulanic acid (Sigma, Saint-Quentin Falavier, France); ticarcillin and
cefoxitin (ROTH, Arlesheim, Switzerland), benzylpenicillin and tazobactam (Abcam, Cambridge, UK);
cefotaxime, gentamicin, and aztreonam (Acros Organic, Geel, Belgium); imipenem (Carbosynth, Berkshire,
UK); avibactam (MedChem Express, Luzern, Switzerland); and ceftolozane (ACS DOBFAR, Tribiano, Italy).
MICs were determined by an agar dilution technique on Mueller-Hinton agar (Bio-Rad, Marnes-la-
Coquette, France) with an inoculum of 104 CFU according to CLSI guidelines (32). All plates were
incubated at 37°C for 18 h. The MICs of -lactams were determined alone or in combination with a ﬁxed
concentration of clavulanic acid (2 g/ml), tazobactam (4 g/ml), or avibactam (4 g/ml). The MIC of
plazomicin was evaluated by the Etest method (Lioﬁlchem, Italy).
In order to rapidly identify by a biochemical-based method whether P. aeruginosa BOR produced an
ESBL or a carbapenemase, both the Rapid ESBL NP and the Rapid Carba NP tests were performed (21, 22).
Molecular characterization and cloning experiments.Whole-cell DNA of P. aeruginosa isolate BOR
was extracted using QiaAmp minikit according to the manufacturer’s recommendations (Qiagen, Courta-
boeuf, France), and DNA was used as a template for the detection of different -lactamases genes using
speciﬁc primers (31).
In order to evaluate and compare the spectrum of hydrolysis of GES-6 to that of GES-1, cloning of the
blaGES-6 and blaGES-1 genes was performed using the broad-host-range pUCp24 vector (30), followed by
expression in the same E. coli TOP10 background (31). Selection was based on plates containing 100 g
of ampicillin per ml plus 30 g of gentamicin per ml. The PCR amplicon encompassing the entire
sequence of the blaGES genes used for cloning was obtained with primers GES-fw (5=-GATGATGAGCTC
TTCCATCTCAAGGGATCACC-3=) and GES-Rv (5=-GATGATGGATCCAGACGGGCGTCAACTATTTG-3=) (31).
Cloning in pUCp24 was performed by BamHI and SacI restriction enzymes. The pUCp24-GES-1 and
pUCp24-GES-6 were transformed in E. coli TOP10 and P. aeruginosa PAO1. Transformants were selected
onto gentamicin containing Luria-Bertani agar plates (15 g/ml).
Genetic context of blaGES-6. In order to assess whether the blaGES-6 gene was indeed located on the
chromosome of P. aeruginosa BOR as reported for the GES-6-producing ST235 isolate FFUP_PS_690 (29),
PCR mapping was performed with a series of primers designed inside and outside the ICE reported in








-Lactamase puriﬁcation. Cultures of E. coli TOP10 harboring plasmid pUCp24-GES-1 and
pUCp24-GES-6 were grown overnight at 37°C in 1 liter of brain heart infusion with amoxicillin
(100 g/ml). The bacterial suspension was pelleted, resuspended in 10 ml of 100 mM phosphate
buffer (pH 7), disrupted by soniﬁcation (20 min for 30 s of sonication and 50 s of rest at 20 kHz with
a Vibra Cell 75186), and centrifuged for 1 h at 11,000  g and 4°C. This suspension was dialyzed
overnight against 20 mM Bis-Tris (pH 6.5) at 4°C (31). The enzyme extract was loaded onto a
pre-equilibrated HiTrap Q HP column (GE Healthcare) with the same buffer. The resulting enzyme
extract was recovered in the ﬂowthrough and dialyzed against 20 mM Tris-HCl (pH 7.5) overnight at
4°C. This extract was then loaded onto a pre-equilibrated (20 mM Tris-HCl [pH 7.5]) HiTrap Q HP
column. Proteins were then eluted with a linear NaCl gradient (0 to 1 M). The fractions showing the
highest -lactamase activity were pooled and dialyzed against 100 mM phosphate buffer (pH 7.0),
prior to a 10-fold concentration with a Vivaspin 20 (GE Healthcare). The puriﬁed -lactamase extract
was immediately used for enzymatic determinations.
Determination of the -lactamase relative molecular mass. The relative purity of -lactamase
GES-6 was estimated by sodium dodecyl sulfate (SDS)–12% polyacrylamide gel electrophoresis analysis.
Enzyme extracts and marker proteins were boiled for 10 min in a 1% SDS–3% -mercaptoethanol
solution and then subjected to electrophoresis (25 mA for 4 h) at room temperature.
Kinetic measurements. Puriﬁed -lactamase was used for kinetic measurements performed at 30°C
in 100 mM sodium phosphate (pH 7.0). The initial rates of hydrolysis were determined with a Genesys 10S
UV-Vis spectrophotometer (Thermo Scientiﬁc). The following wavelengths and absorption coefﬁcients
were used: benzylpenicillin (232 nm/  –1,100 M–1 cm–1), amoxicillin (240 nm/  –1,100 M–1 cm–1),
ticarcillin (235 nm/  –1,050 M–1 cm–1), piperacillin (235 nm/  –1,070 M–1 cm–1), cephalothin
(262 nm/  –7,960 M–1 cm–1), cefoxitin (265 nm/  –7,380 M–1 cm–1), ceftazidime (260 nm/ 
–8,660 M–1 cm–1), cefepime (264 nm/  –8,240M–1 cm–1), cefotaxime (265 nm/  –6,260M–1 cm–1),
ceftolozane (254 nm/  –6,810 M–1 cm–1), imipenem (297 nm/  –9,210 M–1 cm–1), and aztreonam
(318 nm/  –640 M–1 cm–1).
The 50% inhibitory concentrations (IC50s) were determined for clavulanic acid, tazobactam, and avibac-
tam. Various concentrations of these inhibitors were preincubated with the puriﬁed enzyme for 5min at 30°C
to determine the concentrations that reduced the hydrolysis rate of 200M nitroceﬁn by 50%. The results are
expressed in micromolar units. The total protein content was measured by Bradford assay.
The Ki value was determined by direct competition assays using 200 M nitroceﬁn. Inverse initial
steady-state velocities (1/V0) were plotted against the inhibitor concentration ([I]) to obtain a straight line.
The plots were linear and provided y-intercept and slope values used for Ki determination. Ki was
determined by dividing the value for the y-intercept by the slope of the line and then corrected by taking
into account the nitroceﬁn afﬁnity by the following equation: Ki (corrected)  Ki (observed)/(1  [S]/Km)
(33). Here, “[S]” is the concentration of nitroceﬁn (200 M) used in the assay and Km is the Michaelis
constant determined for nitroceﬁn (108 M for GES-6 and 115 M for GES-1). Progress curves with a ﬁxed
concentration of enzyme and nitroceﬁn, and increasing inhibitor concentrations were used to determine
the kinact and KI values, as previously described. The kobs was plotted versus the inhibitor concentrations
of the experiment and ﬁt to determine kinact according to the following equation: kobs  kinact[I]/(KI  [I])
(34). The KI value obtained was corrected using the same equation as that used to calculate the Ki. To
calculate kinact, the kobs versus kobs/[I] value was plotted, considering the following: V0  Vmax – Km 
(V0/[S]) ¡ Kobs  kinact – KI  (Kobs/[I]).
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